NCT00237627: Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 107 | US | PS-341, Doxil, pegylated liposomal doxorubicin, Velcade, Bortezomib | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 12/06 | 01/10 | | |
NCT00331552: Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer |
|
|
| Completed | 1/2 | 30 | US | pegylated liposomal doxorubicin hydrochloride, CAELYX, Dox-SL, DOXIL, doxorubicin hydrochloride liposome, Evacet, LipoDox, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, Enduxan, trastuzumab, anti-c-erB-2, Herceptin, MOAB HER2, monoclonal antibody c-erb-2, monoclonal antibody HER2 | University of Washington, National Cancer Institute (NCI) | HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer | 02/11 | 02/12 | | |
